Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Cancer Causes Control. 2018 Dec 12;30(1):103–112. doi: 10.1007/s10552-018-1117-x

Table 1.

CYP2D6 inhibitors observed in study, by inhibitor strength and exposure classification

Exposure classification
Strength Medications Any
inhibition
Strong or
moderate
Strong
only
Strong bupropion, fluoxetine, paroxetine X X X
Moderate duloxetine, sertraline X X
Weak or unknown amiodarone, celecoxib, citalopram, clomipramine, diltiazem, doxepin, escitalopram, hydralazine, oral contraceptives, propafenone, verapamil X